Close Brothers Seydler Research AG: BB Biotech - Good start in FY 2011 with profit in 1Q
The 1Q 2011 figures with a net profit of CHF 39.61m are a good start into FY 2011, similar to 1Q 2010. Net gains from marketable securities was CHF 42.73m and mainly driven by the good stock price performance of Gilead and Vertex. Bitte lesen Sie den Bericht auf Englisch im pdf-Dokument.13.05.2011 | 11:13 Uhr